Bemcentinib Completed Phase 2 Trials for Stage IV Non-small Cell Lung Cancer (NSCLC) / Adenocarcinoma of the Lung / Metastatic Lung Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03184571Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC